经鼻高流量氧疗在重症支气管哮喘合并呼吸衰竭患者临床治疗中的应用研究

Study of the Clinical Value of High-flow Nasal Cannula Oxygen Therapy in Severe Bronchial Asthma Patients with Respiratory Failure

目的:研究经鼻高流量湿化氧疗(HFNC)在重症支气管哮喘(SBA)合并呼吸衰竭患者治疗中的应用价值。方法:将某院2019年1月~2020年12月期间收治的120例SBA合并呼吸衰竭患者随机分为C组和C+H组各60例,分别实施常规治疗联合常规鼻导管吸氧、常规治疗联合HFNC。治疗前后分别检测血气指标(PaO_(2)、PaCO_(2)、SaO_(2)),并予以APACHEII评分、哮喘ACT评分。结果:治疗24h后,C+H组患者PaO_(2)、SaO_(2)均高于C组(P<0.05),PaCO_(2)低于C组(P<0.05);治疗72h后,C+H组APACHEII评分低于C组(P<0.05),哮喘ACT评分高于C组(P<0.05)。结论:SBA合并呼吸衰竭患者采用HFNC治疗可有效提供患者呼吸支持,改善呼吸功能,控制哮喘和呼吸衰竭病情。

Objective:To study the application value of high-flow nasal cannula oxygen therapy(HFNC)in the treatment of severe bronchial asthma(SBA)complicated with respiratory failure.Methods:120 patients with SBA complicated with respiratory failure admitted to a hospital from January 2019 to December 2020 were randomly divided into group C(n=60)and group C+H(n=60),who received conventional treatment+conventional nasal catheter oxygen inhalation and conventional treatment+HFNC,respectively.Blood gas indexes(PaO_(2),PaCO_(2),SaO_(2))were detected before and after treatment,APACHEII score and asthma ACT score were evaluated.Results:After 24h of treatment,PaO_(2)and SaO_(2)in group C+H were higher than those in group C(P<0.05),and PaCO_(2)was lower than that in group C(P<0.05).After 72 hours of treatment,the APACHEII score of group C+H was lower than that of group C(P<0.05),and the asthma ACT score of group C+H was higher than that of C group(P<0.05).Conclusion:HFNC treatment for SBA patients with respiratory failure can effectively provide patients respiratory support,improve respiratory function,and control asthma and respiratory failure.